Truffle Capital collects €390m across two venture funds
French venture firm Truffle Capital has closed its BioMedTech fund on €250m and Fintech-Insurtech vehicle on €140m...
Truffle Capital a levé 390 millions pour deux nouveaux fonds
Les nouveaux véhicules seront consacrés aux medtechs (250 millions d'euros) et aux fintechs (140 millions d'euros).
Truffle Capital Raises €250M Fund to Launch Life Science Startups
The French VC firm Truffle Capital has closed a fund worth €250M with a mission to nurture companies specializing in medical devices
Consortium with Nestlé Waters, PepsiCo and Suntory Beverage & Food
Impressive 12-month Efficacy and Safety Data from ABX464
FDA approval to launch a clinical feasibility study in the United States
Inclusion du premier patient dans l’essai clinique de Phase 2b (ABX464-103) d’Abivax visant le traitement de la rectocolite hémorragique
Le critère d'évaluation principal est la réduction du score de Mayo à 8 semaines. Les critères d'évaluation secondaires incluront la rémission clinique, l'amélioration constatée par endoscopie ainsi que la mesure du biomarqueur…
Inclusion of the first patient in Abivax's Phase 2b (ABX464-103) clinical trial for the treatment of hemorrhagic rectocolitis
The main evaluation criterion is the reduction of Mayo's score to 8 weeks.
Abivax treats first rheumatoid arthritis patient in Phase 2a clinical trial
The clinical trial was approved in the following four European countries: France, Poland, Czech Republic and Hungary. ABX464 is a drug candidate in oral adent tablet form with an innovative mechanism of action and has already demonstrated positive results in hemorrhagic rectocolitis, another chronic inflammatory disease with a biological profile closely similar to rheumatoid arthritis.
1st PET bottles from 100% biorecycled plastic waste
ABIVAX Completes €12 Million Capital Raise Entirely Subscribed by Sofinnova Partners at Market Price
FDA grants Fast Track designation for the development of PTX3003 in the treatment of patients with Charcot-Marie-Tooth disease type 1a
Positive interim results from the first part of the PIVOT study
Positive interim results from the first part of the PIVOT study (10 patients), 70% of patients in this first cohort achieved a six-month survival with the bioprosthesis or a successful total transplant, healthy heart within 6 months of implantation of the device.